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Abstract
Fragile X Syndrome is caused by the silencing of the Fragile X Mental Retardation gene (FMR1). Regulating dosage of FMR1
levels is critical for proper development and function of the nervous system and germ line, but the pathways responsible for
maintaining normal expression levels are less clearly defined. Loss of Drosophila Fragile X protein (dFMR1) causes several
behavioral and developmental defects in the fly, many of which are analogous to those seen in Fragile X patients. Over-
expression of dFMR1 also causes specific neuronal and behavioral abnormalities. We have found that Argonaute2 (Ago2),
the core component of the small interfering RNA (siRNA) pathway, regulates dfmr1 expression. Previously, the relationship
between dFMR1 and Ago2 was defined by their physical interaction and co-regulation of downstream targets. We have
found that Ago2 and dFMR1 are also connected through a regulatory relationship. Ago2 mediated repression of dFMR1
prevents axon growth and branching defects of the Drosophila neuromuscular junction (NMJ). Consequently, the
neurogenesis defects in larvae mutant for both dfmr1 and Ago2 mirror those in dfmr1 null mutants. The Ago2 null
phenotype at the NMJ is rescued in animals carrying an Ago2 genomic rescue construct. However, animals carrying a
mutant Ago2 allele that produces Ago2 with significantly reduced endoribonuclease catalytic activity are normal with
respect to the NMJ phenotypes examined. dFMR1 regulation by Ago2 is also observed in the germ line causing a multiple
oocyte in a single egg chamber mutant phenotype. We have identified Ago2 as a regulator of dfmr1 expression and have
clarified an important developmental role for Ago2 in the nervous system and germ line that requires dfmr1 function.
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Introduction
Fragile X mental retardation syndrome is the most common
heritable form of mental retardation and known cause of autism. In
mammals, the dosage of Fragile X expression is critical to the distinct
diseases related to this locus. In most patients with Fragile X
syndrome, the FMR1 gene is transcriptionally silenced when the
CGG triplet repeat in the 59-untranslatedregion(UTR)ismethylated
upon expansion to greater than 200 copies [1,2,3]. Over-expression
of the CGG containing FMR1 transcript itself is linked to both an
independent neurodegenerative disease, Fragile X-associated trem-
or/ataxia syndrome (FXTAS) and to premature ovarian failure
[4,5,6,7,8,9]. It is not fully understood how the steady state levels of
the FMR1 gene are normally regulated; however, it is clear that tight
regulation, both positive and negative, isrequired forproperneuronal
and germ-line function and maintenance (Reviewed in [10]).
The Drosophila melanogaster Fragile X model, based on the single
DrosophilafragileXmentalretardationgene(dfmr1),hasprovenitselfafacile
system for understanding aspects of the genetic, molecular, cognitive
and morphological defects that affect Fragile X and FXTAS patients
(Reviewed in [11]). dFMR1 shares extensive homology with human
FMR1 in the RNA binding motifs: the K homology (KH) domains
and the RGG-type RNA-binding domain [12,13,14,15]. Similar to
FMR1, dfmr1 mRNA is expressed throughout development with the
highestlevelsseeninneuronsandtheDrosophilagermline[15,16,17].
Like its human counterpart, regulation of dfmr1 is required for
normal neuronal development and function. Over-expression of
FMR1 in a mouse model system has been shown to result in
abnormal behavioral and neurological activities [18,19]. Analogous-
ly, over-expression of dFMR1 in the brain causes behavioral defects,
axon guidance and extension defects, and dendritic branching
abnormalities [20,21,22,23,24]. Both the human and Drosophila
fragile X proteins bind their own mRNA and are involved in
translational regulation [25,26,27]. Interestingly, the dFMR1
protein has been shown to act as both a negative regulator of target
transcripts, such as Futsch and pickpocket, and a positive regulator of
target transcripts, such as Trailer Hitch [27,28,29].
Although dFMR1 is hypothesized to act as a translational
regulator, no single mechanism has emerged to explain how
dFMR1 regulates its targets. One potential mechanism for how
dFMR1 could function as a translational regulator is based on the
physical association between dFMR1 and Argonaute2 (Ago2), the
core component of the small interfering RNA (siRNA) pathway
[29,30,31]. Specifically, Ago2 functions as an endoribonuclease in
a protein complex bound to short RNAs that serve as guides to
target specific transcripts for degradation (Reviewed in [32]).
Because dFMR1 was found to be present in the functional siRNA
induced silencing complex (siRISC) with Ago2, it was hypothe-
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associated translational regulation. Additionally Ago2 and dFMR1
were also shown to co-regulate a target mRNA suggesting that
these two proteins function coordinately[29]. However unlike
Ago2, which is required for siRNA mediated silencing, dFMR1
has been shown to have little to no effect on siRNA efficiency, and
is therefore thought to play a stabilizing or modifying role in
siRISC function [29,30,31].
Ago2 has been well characterized as the core component of the
siRNA pathway and the endogenous siRNA pathway, yet fewer
studies have examined the biological role of Ago2 in animal models.
Ago2 has been shown to be important in larval behavior and proper
embryogenesis but the pathways and mechanisms by which these
Ago2 mediated processes occur are unknown [29,33,34].
The aim of our research was to determine how Ago2 and
dFMR1 interact genetically in two developmental systems known
to be dependent on dFMR1 expression, the neuromuscular
junction and the female germ line. By looking at dFMR1
expression in a variety of genetic backgrounds and in different
tissue types, we have found that Ago2 regulation of dFMR1 in the
nervous system and the germ line is necessary for proper
neurogenesis and oogenesis.
Results
Loss of Ago2 causes defects in synaptic structure that are
dependent on dfmr1
It was previously shown that dFMR1 is expressed in the pre-
synaptic motor neurons and post-synaptic muscles in larvae [27].
Effects from changes in dFMR1 levels have been well character-
ized in the larval neuromuscular junction (NMJ), which is an
excellent model to study synaptic structure [27]. dfmr1 null animals
have over-elaborated synaptic termini with an increased number
of smaller synaptic boutons. In contrast, the over-expression of
dFMR1 leads to a decreased number of larger synaptic boutons
and a loss of synaptic branching. For consistency we carried out all
of our studies of the NMJ in the same abdominal hemisegment (3),
and muscle (6/7) in third instar wandering larvae. The bouton
number and branch numbers of the synaptic termini were
quantified using anti-cysteine string protein and DAB staining
visualized with a light microscope. Additionally we used anti-HRP
to observe the gross morphology of the larval NMJ architecture of
the same abdominal hemisegment (3), and muscle (6/7) using a
maximum projection from a stack of confocal sections through the
NMJ (Figure 1A).
The larval NMJ from two independently isolated Ago2 null
strains, Ago2
51B [29] and Ago2
414 [35], exhibited a significant
under-elaboration of the synapse with a 34% decrease in the
number of boutons in comparison to the wild-type larval NMJ
(WT) (Figure 1). To verify that the NMJ defects observed in the
Ago2 null mutants were due to loss of Ago2 activity and not genetic
background, we also analyzed larvae carrying a genomic Ago2
transgene in an Ago2 null background, P{Ago2}; Ago2
414 larvae
[35]. Both the bouton and branching phenotypes observed in Ago2
null larvae were rescued in the P{Ago2};Ago2
414 larvae. The NMJ
phenotype observed in Ago2 null larvae was strikingly similar to
that observed in larvae where dFMR1 is over-expressed using the
UAS/GAL4 system [27]. Similarly, transgenic larvae carrying
Figure 1. Ago2 affects synaptic development and morphology similarly to dFMR1 over-expression. (A) Representative images show
third instar larval, abdominal hemisegment 3, muscle 6/7 of the NMJ marked with Texas-Red conjugated HRP. dfmr1(4X), Ago2
414, and Ago2
51B NMJs
show under-elaborated branching, whereas dfmr1 null and Ago2
51B, dfmr1
3 double mutants show over-elaboration of branching patterns, and
P{Ago2};Ago2
414 and Ago2
V966M are similar to WT. Scale bar is 41.66 mm for WT, dfmr1(4X), dfmr1
3, Ago2
51B, and Ago2
51B, dfmr1
3, and Ago2
V966M (the
Ago2
V966M allele is presented here although its significance is discussed later in the results section). Scale bar is 50 mm for P{Ago2};Ago2
414, and
Ago2
414. (B and C) Quantification of structural phenotypes at the synapse. Numbers of type I synaptic boutons (B) and numbers of type I synaptic
branches (C) are quantified for abdominal hemisegment 3, muscle 6/7 of the NMJ. For all genotypes, n$13. *P,0.001 and **P,0.0001 using one-way
ANOVA followed by Dunnett’s test. Data are graphed as mean 6 s.d.
doi:10.1371/journal.pone.0007618.g001
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the synapse with a 36% decrease in the number of boutons in
comparison to WT (Figure 1).
To determinewhether dFMR1was requiredfor the Ago2nullNMJ
phenotype, we carried out genetic epistasis analyses. The dfmr1 null
(dfmr1
3) larvae displayed an opposite NMJ phenotype in comparison
to the larvae that over-express dfmr1.L o s so fdfmr1 resulted in over-
elaboration of the synaptic termini with a 48% increase in the
number of boutons and 81% increase in the number of synaptic
branchesincomparison to WT, similar to the phenotypes observed in
the mammalian nervous system of FMR1 mutants and Fragile X
patients (Figure 1) [36,37,38,39]. If dFMR1 over-expression were
required for the Ago2 null phenotype, then we would expect that
Ago2
51B,d f m r 1
3 double mutant animals would resemble dfmr1
3
animals. Ago2
51B,d f m r 1
3 double mutant larvae did indeed display a
dfmr1 null-like phenotype with respect to the gross morphology of the
NMJ. Specifically, we observed a 45% increase in the bouton
numbers from Ago2
51B,d f m r 1
3 double mutant larvae compared to
wild-type larvae, and an 87% increase in synaptic branch numbers
(Figure 1). We therefore were able to conclude that loss of Ago2
expression alters the larval NMJ synaptic structure through dFMR1.
Ago2 regulates dFMR1 in the adult nervous system
To determine whether the larval NMJ phenotype observed in
Ago2 null larvae was actually due to over-expression of dFMR1 as
was suggested by the genetic studies, we examined how loss of
Ago2 affected dFMR1 expression in adult brains. Immunohisto-
chemistry analyses in whole-mount brains revealed that the
expression of dFMR1 is more than four-fold higher in brains
from Ago2
51B and Ago2
414 flies compared to expression in wild-type
brains (Figure 2). Loss of Ago2 did not affect the spatial patterns of
dFMR1 expression in the adult brain. In addition, no gross
morphological mutant phenotypes were observed in the Ago2 null
fly brains (Figure 2). Western analysis of whole head extracts
prepared from control and Ago2 null flies also showed similar up-
regulation of dFMR1 protein levels (Figure S1A, B).
Ago2 regulates dFMR1 during oogenesis
Previously we had observed that tight regulation of dFMR1 was
required in the female germ line for proper development, therefore
we asked whether Ago2 regulated dFMR1 in other non-neuronal
tissues such as the ovaries. We analyzed dFMR1 expression
throughout oogenesis using immunofluorescence staining on
ovaries from both Ago2 null strains. dFMR1 is normally enriched
in the oocyte but present throughout the egg chamber at low levels
[40]. The ovaries from flies lacking Ago2, maintained the wild-
type enrichment of dFMR1 in the oocyte (Figure 3 and [40]).
Paralleling results from adult brains, quantitative comparisons of
dFMR1 expression levels in ovaries from both Ago2 mutants and
WT ovaries revealed up-regulation between 2–4 fold of dFMR1
protein levels throughout the Ago2 null egg chambers (Figure 3).
Additionally, levels of DE-cadherin, a cell adhesion molecule, were
consistent in egg chambers from all genotypes, substantiating the
uniformity of the staining technique. Co-staining with anti-
dFMR1 and anti-DE-cadherin also demonstrated that the up-
regulation of dFMR1 observed in Ago2 null egg chambers was
likely specific and not due to global regulation of translation or
protein stability by Ago2. Western analyses of extracts prepared
from control and Ago2 null ovaries also revealed similar up-
regulation of dFMR1 protein levels (Figure S1C, D).
Figure 2. Loss of Ago2 results in increased dFMR1 in adult heads. (A) Representative whole-mount brains labeled for dFMR1 (green) from
WT, Ago2
51B, Ago2
414, and dfmr1
3 flies. Scale bar is 100 mm. (B) Graphical representation of fold increase in fluorescence (representing dFMR1)
intensity relative to WT as quantified by Leica TCS SP quantification software (n$5 for each genetic background). See Materials and Methods for
details. Data are graphed as mean 6 s.d.
doi:10.1371/journal.pone.0007618.g002
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PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7618Figure 3. Loss of Ago2 results in increased dFMR1 in oogenesis. Representative images of whole-mount ovaries labeled for dFMR1 (green)
and DE-cadherin (blue) from WT, Ago2
51B, Ago2
414, and dfmr1
3 flies. Scale bar is 28.63 mm. The graphs plot the pixel intensity (0 to 255 as quantified by
Leica software) versus position (mm) along a line drawn through the egg chamber (seen in the merged image) (n$10 for each genetic background).
See Materials and Methods for details.
doi:10.1371/journal.pone.0007618.g003
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over-expression
Egg chambers from dfmr1
3 null flies display multiple oogenesis
defects at a low penetrance, including two oocytes mis-specified in
a single egg chamber [40]. Notably, dfmr1(4X) over-expression flies
also displayed the rarely seen phenotype of two oocytes mis-
specified in a single egg chamber (instead of a single oocyte in a
single egg chamber), using the cytoplasmic polyadenylation
element binding protein homologue, Orb, as an oocyte marker
(Figure 4A). Although there were no gross morphological mutant
phenotypes observable in the majority of Ago2 null egg chambers,
we did observe that the loss of Ago2 resulted in the two oocytes
mis-specified in a single egg chamber defect at a low penetrance
(Figure 4A). To quantify this phenotype we carried out ovary
staining with the synaptonemal complex component marker c(3)G
in order to see early mis-specification of two oocytes [41]. We
found that dfmr1(4X) flies displayed this phenotype at 7.3%
penetrance (n=122) (Figure 4B, C). We observed the defect at
4.3% (n=137) in the Ago2 null egg chambers (P,0.05) in
comparison to a penetrance of 0.6% (n=155) in the wild-type
egg chambers (Figure 4C). Further genetic epistasis analyses based
on the double oocyte phenotype were not possible because both
gain and loss of dFMR1 expression caused the same defects in
oogenesis.
Ago2 regulates dfmr1 transcript levels during oogenesis
To determine how Ago2 regulates dFMR1 expression, we
analyzed how loss of Ago2 affects dfmr1 steady-state transcript
levels in adult ovaries using quantitative real-time PCR (QT-PCR)
and Northern analyses (Figures 5 and S2). Because we observed
dFMR1 up-regulation in Ago2 null egg chambers, we conducted
QT-PCR and Northern analyses in RNA lysates from ovaries in
which we could easily isolate mass amounts of tissue materials. We
detected an average of 1.5 fold increase in dfmr1 transcript levels
from Ago2 null ovaries in comparison to dfmr1 transcript levels
from wild-type ovaries (Figures 5 and S2). The difference between
the fold up-regulation of dfmr1 mRNA (,1.56) compared with the
Figure 4. Loss of Ago2 results in a developmentally abnormal oocyte phenotype. (A) A two-oocyte mis-specification defect (marked with
arrows) in a single late-stage egg chamber as observed by ectopic expression of Orb. Whole-mount ovaries labeled for dFMR1 (green) and Orb (red)
from dfmr1(4X), dfmr1
3, and Ago2
51B flies. Scale bar is 100 mm. (B) A two-oocyte mis-specification defect in a single early egg chamber as observed by
c(3)G expression. A single synaptonemal complex is present in a WT egg chamber, whereas egg chambers from dfmr1(4X) and Ago2
51B flies display
two synaptonemal complexes (marked with arrows). Scale bar is 50 mm. (C) Penetrance of two-oocyte mis-specification defect. Percentage of egg
chambers displaying the oocyte defect is shown on the y-axis as visualized by counting stage 6–10 egg chambers marked with anti-c(3)G staining of
WT, dfmr1(4X), and Ago2
51B ovaries. WT (n=155), dfmr1(4X) (n=122), Ago2
51B (n=137). *P,0.05 and **P,0.005 using a one-sided Fisher exact test.
doi:10.1371/journal.pone.0007618.g004
Figure 5. Ago2 regulates dfmr1 mRNA. dfmr1 and rp49 transcript
levels were measured in four biological replicates using quantitative
real time PCR (QT-PCR) from ovary cDNA from WT, dfmr1(4X), and
Ago2
51B flies. QT-PCR for dfmr1 was normalized to rp49. QT-PCR for rp49
was normalized to 28S. Data are graphed as mean fold change relative
to WT 6 s.e.m.
doi:10.1371/journal.pone.0007618.g005
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the Ago2 null strain suggests that dfmr1 translational efficiency may
be affected by the loss of Ago2. To test whether Ago2 induces a
general down-regulation of transcript levels during oogenesis, QT-
PCR was used to detect the levels of another transcript, rp49,
which codes for ribosomal protein RpL32. No change in rp49
mRNA levels was observed in the Ago2 null background (Figure 5).
Is the dfmr1 transcript a target of the endogenous siRNA
pathway?
We next wanted to determine whether the dfmr1 transcript was
being directly regulated through the canonical endogenous siRNA
pathway that uses processed long dsRNA to target and degrade
mRNAs. The mir-34 locus is less than 400 bp downstream of dfmr1
and is transcribed in the opposite direction relative to dfmr1.
Transcription of both genes could provide a potential source of
dsRNA that could serve as a substrate for the siRISC. We failed to
detect specific small RNAs from the dfmr1 region using Northern
analyses and no significant matches to the dfmr1 locus were
detected from deep sequencing results from small RNAs isolated
from ovaries, heads and S2 cell lines (data not shown and the
generous sharing of unpublished data and personal communica-
tion from G. Hannon and P. Zamore). These data suggest that
dfmr1 is not likely a direct target of the canonical endogenous
siRNA pathway.
Is Ago2 cleavage activity required for dfmr1 regulation?
Based on the data above, which suggests that dfmr1 is not a
direct target of the endogenous siRNA pathway, we questioned
whether Ago2 might play a unique role in regulating dfmr1 that
does not require Ago2 cleavage activity. To answer this question,
we examined how dfmr1 was regulated in another Ago2 mutant fly-
strain, Ago2
V966M. The Ago2
V966M flies carry a point mutation that
reduces the cleavage activity of Ago2 by eight-fold, but does not
affect the expression levels of Ago2 [42]. If Ago2-dependent
catalysis of the dfmr1 transcript or any other transcript were
required for regulation of dfmr1, then we would expect to see an
Ago2 null-like larval NMJ phenotype in the Ago2
V966M larval NMJs
in comparison to wild-type larval NMJs. Unlike the NMJ analyses
of Ago2 null larvae, the bouton and branching numbers from
Ago2
V966M larval NMJs were similar to wild-type NMJs (Figure 1).
Additionally, dFMR1 was not up-regulated in Ago2
V966M mutant
egg chambers (Figure S3), suggesting that Ago2 suppresses
dFMR1 expression through a mechanism that bypasses a
functional Ago2 catalytic domain.
Discussion
Dosage of Fragile X expression must be tightly regulated to
prevent the deleterious effects seen in either loss- or gain-of-
function models observed in mice, Drosophila, and most impor-
tantly human patients. To our knowledge, three regulators of the
Drosophila Fragile X protein had been previously reported
[24,43,44]. Here, we provide genetic evidence that dFMR1 is
also regulated by Ago2 in the nervous system and in the germ line.
This finding is exciting and novel in that to our knowledge Ago2
has not been previously shown to regulate the protein levels of an
endogenous target in the nervous system and germ line and few
other endogenous protein targets have been identified [34].
It has become clear in the last decade that mechanisms of
translational control are fundamental for proper synaptic function
related to learning and memory [45]. Furthermore, components of
the RISC pathway have also been shown to localize to the synapse
in Drosophila where they are involved in translational regulation, and
to the peripheral nerve axons in mammals [46,47]. Our findings,
alongwiththeaforementioned,supportthe conclusionthatAgo2,in
additionto otherRISC pathway components areactivewhererapid
translation in response to cell signaling is required.
Because siRNA pathway mutants are not lethal like their micro
RNA (miRNA) counterpart mutants, and do not exhibit gross
morphological defects, a potential regulatory role for the siRNA
pathway during development has been overshadowed. We have
shown that loss of Ago2, a core member of the siRNA pathway,
causesspecific and significant defects in neurogenesis and oogenesis.
The neurological defects we observed in Ago2 mutants require
dFMR1, suggesting that the role of Ago2 in neuronal development
might also include additional dFMR1 specific and/or novel
functions. Defects in synaptic architecture that are caused by loss
of or elevation of dFMR1 levels have functional consequences at the
glutamatergic NMJ synapse [27]. Zhang et al. observed that loss of
dFMR1 results in elevated evoked synaptic transmission whereas
pre-synaptic dFMR1 over-expression results in elevated spontane-
ous vesicle fusion[27]. We are interested in determining whether
Ago2 mutants might also exhibit elevated spontaneous vesicle fusion
affecting Drosophila learning and memory.
In the studies reported here, we focused on the biological
implications and regulation of one disease-related target, dfmr1,b y
the siRNA pathway component Ago2. Several endogenous siRISC
targets have been identified using global analyses such as micro-
arrays and deep sequencing of small RNAs [48,49,50,51,52].
However, few Ago2 targets have been characterized with respect
to how mis-regulating such targets might impact the development of
Ago2 mutant animals. In Drosophila, the neuronal ion channel
pickpocket (ppk) has been shown to be up-regulated in animals mutant
for Ago2 [29]. We noted similarities between the regulation of dfmr1
and ppk by Ago2, perhaps suggesting a shared regulatory mechanism
as well. Both ppk and dfmr1 expression were elevated to similar levels
due to loss of Ago2 [29]. The differential increase between dFMR1
protein and mRNA levels in an Ago2 null animal suggests that Ago2
activity results in post-transcriptional regulation of dfmr1.W e
hypothesize that Ago2 might regulate its targets in a protein
complex that acts to regulate the stability and/or translational
efficiency of the mRNA. However, we have not yet ruled out that
Ago2 might also regulate gene expression at the protein level by
altering the stability or overall activity of the protein. The specific
post-transcriptional mechanisms that Ago2 utilizes to regulate gene
expression remain unknown for Ago2 targets such as dfmr1 and ppk.
We also examined previous studies of Ago2 to understand how
Ago2 might regulate dfmr1 with diminished ribonuclease cleavage
activity. Ago2 is required for normal formation of processing bodies
or P bodies (ribonucleoprotein aggregates containing enzymes
involved in mRNA decay and miRNA associated translational
regulation) in S2 cells [53–55]. Ago2 has been shown to localize to
neuronal granules in primary cell culture of Drosophila larval central
nervous system (CNS) cells [56]. Additionally, Ago2 has also been
shown to protect poly-A tail length of a target transgene in S2 cells
[57]. Allof these associated properties of Ago2 have not beenshown
to require a siRNA intermediate, and may help to elucidate a
general mechanism for how Ago2 regulates targets such as dfmr1.
Whether Ago2 might be acting in a complex with other siRNA
pathway members or the dFMR1 protein itself to regulate dfmr1
expression also remains to be investigated.
Materials and Methods
Drosophila stocks
The following Drosophila stocks were used: WT (w
1118), dfmr1(4X)
(w
1118; P{WTR-dfmr1})[20], dfmr1
3 (dfmr1
3/Tm6C,Tb,Sb) [20],
dfmr1 is Regulated by Ago2
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51B (Ago2
51B/Tm3,Sb,GFP)[29], Ago2
414 and P{Ago2
414};
Ago2
414 [35], Ago2
V966M [42], and Ago2
51B,dfmr1
3/Tm3,Sb,GFP
(made by standard recombination procedures and verified by
genomic PCR).
Immunohistochemistry
Brains were dissected in 1X PBS and fixed in 4% paraformal-
dehyde (PFA)/PBST (1X PBS +0.2% Triton-X 100), for 20
minutes at RT. Brains were washed in PBST, blocked in 5%
Normal Goat Serum (NGS) for 1 hour at 4uC and incubated in
primary antibody overnight at 4uC. Brains were washed and
incubated in secondary antibody for 2 hours at RT. Brains were
mounted in Mounting Medium (KPL 71-00-16). Ovaries were
stained in the same manner as described for the brains except that
they were dissected in 1X Robbs (55 mM sodium acetate, 40 mM
potassium acetate, 100 mM sucrose, 10 mM glucose, 1.2 mM
MgCl2, 1 mM CaCl2, 100 mM HEPES [pH 7.5]) and fixed in
4%PFA/PBS. Ovary staining with anti-c(3)G was done as
described previously [41]. Primary antibodies used were: anti-
dFMR1 (6A15) 1:1000 [15], anti-Orb (6H4) 1:30 (Developmental
Studies Hybridoma Bank, Iowa), anti-DE-cadherin (DCAD2) 1:20
(DSHB, Iowa) and anti-c(3)G 1:500, a kind gift from Scott Hawley
[41]. Secondary antibodies used were: FITC-conjugated goat anti-
mouse IgG1 1:500 (Southern Biotech), Texas Red-conjugated goat
anti-mouse IgG2a 1:500 (Southern Biotech), and Cy5-conjugated
donkey anti-rat 1:350 (Jackson ImmunoResearch).
Immunohistochemistry of larval NMJ
Preparations were fixed and stained as previously reported with
the following modifications [58,59]: third instar wandering larvae
were dissected along the dorsal midline in Ca
2+ saline, pinned flat
onto dishes coated in Sylgard (Dow-Corning), and fixed for either
45 minutes (anti-CSP staining at 1:200) [60] or 25 minutes (Texas
Red-conjugated HRP staining at 1:200 (JacksonImmunoResearch))
in 4% PFA/PBS. All anti-CSP DAB stained preparations used to
quantify synaptic boutons were mounted in Cytoseal XYL
mounting medium (Richard-Allan Scientific). Fluorescent prepara-
tions used to visualize gross synaptic morphology were mounted in
Vectashield mounting medium (Vector laboratories). A stack of
images was taken to capture a 2-dimensional image through the
entire depth of the NMJ, and presented in Figure 1A as a maximum
projection for each genotype. Anti-CSP staining was visualized
using a Vectastain ABC Elite Kit with NiCl2 enhancement and
imageswerequantifiedat 1000Xusing a LeicaDMEmicroscope. A
Leica TCS SP confocal microscope using software version 2.6.1 was
used to capture the maximum projection from multiple sections of
Texas Red-conjugated-HRP images at 600X.
NMJ morphological analysis
Quantification of the NMJ morphology in larvae was done as
described with the following modifications [58,59]. Anti-CSP
stained type I boutons at the muscle 6/7 NMJ of abdominal
hemisegment 3 were quantified in w
1118, dfmr1
3, dfmr1(4X),
Ago2
414, P{Ago2};Ago2
414, Ago2
51B and double mutant Ago2
51B,
dfmr1
3 larvae. The number of boutons was averaged for all larval
hemisegments counted (n$13) from each genetic background.
Branch numbers were counted as previously described [59].
Statistical analyses were performed using one-way ANOVA
followed by Dunnett’s test.
Microscopy
All confocal images were taken with the Leica TCS SP confocal
microscope using software version 2.6.1. The experiments shown
in Figure 2 were completed as a single set, as defined below. The
experiments shown in Figure 3 were completed as a single set. The
experiments shown in Figure S3 were completed as a single set. A
single set of images is defined as follows: for each set, images for all
genotypes were taken at the same time, with the same documented
settings, including pixel size, resolution, dimensions, hardware
parameters, laser and scanner settings. Figures 1 and 4 (which
were not quantitative images) were assembled with images taken at
different photomultiplier tube settings. Quantification for
Figures 2, 3 and S3 were calculated using the Leica TCS SP
quantification software. For Figures 3 and S3, one line of identical
length was drawn through one focal plane of each image (average
of 4 scans) for each set. Leica quantification software plots the pixel
intensity (0–255) versus position along that line (mm) for each
channel acquired (anti-dFMR1 and anti-DE-cadherin using
sequential scanning). This process was carried out on multiple
egg chambers (n$10) and repeated in multiple staining experi-
ments. A representative image was chosen for the figures. For
Figure 2, due to the non-uniform staining of dFMR1 in the brain,
the mean fluorescent intensities within three defined regions of
interest (ROI) (same areas and dimensions of ROIs kept for all
images) were averaged. This process was carried out in multiple
brains (n.5) from each genetic background. The mean intensity of
the background staining observed in dfmr1 null flies was subtracted
from the mean fluorescent intensity measured in each ROI of each
genetic background before normalization to WT to calculate the
fold change.
Quantitative RT-PCR
Ovary pairs from 3–6 day old females were dissected in 1X
Robbs buffer. Total RNA from ovaries was extracted using TRI
Reagent (Ambion) and bromochloropropane (BCP) for RNA
extraction, and was further purified using columns from RNeasy
Mini Kit (Qiagen) and on-column treatment with Qiagen DNase
I. 0.5 mg RNA was used to generate cDNA using random
hexamers (Invitrogen Superscript III kit). Real-time PCR was
carried out using SYBR GreenER qPCR superMix Universal
(Invitrogen) and the Mx3005P PCR system (Stratagene). We
carried out four biological replicates with four separate RNA pools
and four separate reverse transcription reactions for ovary
experiments. Subsequently, each biological replicate was run in
triplicate technical replicates for QT-PCR analyses. Cycling
program was as follows: 95uC for 10 minutes, 40 cycles of 95uC
for 30 seconds, 60uC for 1 minute, 72uC for 30 seconds followed
by a melting curve analysis. Analyses were carried out using
median cycle threshold (CT) values and normalization to rp49 or
28S as internal controls. Sequences for QT-PCR primers: 59
TGGTCAATGGCACGTCCTAA (forward) and 59 TTCTAGC-
CATCTGTGAGCTGTTG (reverse) for dfmr1. Primer sequences
for rp49 and 28S were as described [61].
Northern Analysis
Total RNA from ovaries was isolated using the RNeasy Mini
Kit with Qiashredder columns (Qiagen). Northern analysis was
performed using the NorthernMax-Gly kit (Ambion) as described
by the manufacturer’s instructions with the following modifica-
tions. 25 mg total RNA was run per lane. Ambion Bright-Star
membranes pre-hybridized in ULTRAhyb (Ambion) for 30
minutes at 68uC, and probed overnight with
32P-labeled dfmr1
fragment or
32P-labeled b-tubulin fragment, which served as a
loading control. Probes were synthesized and removed using the
StripAble RNA probe synthesis and removal kit (Ambion).
Sequences of primers used to generate Northern probes 59
AAGAAGCCCAGAAGGATGGT (forward) and 59 T7 +
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7618TTCTCCTCCAGCTCGATGTT (reverse) for dfmr1 and 59
CTGGAGCGCATCAATGTGTA (forward) and 59 T7 +
TGTGTGAGTTGGAAGCCTTG (reverse) for b-tubulin. RNA
levels were assessed using phosphorimaging techniques and Image
Quant software (version 2.4).
Western Analysis
Ovaries from 3 day-old females fed on grape plates or heads
were dissected in 1X Robbs buffer. Extracts were prepared using
extraction buffer (20 mM HEPES (pH 7.5), 100 mM KCl, 5%
glycerol, 100 mM Na3VO4, 10 mM EDTA, 0.1% Triton-X,
1 mM DTT, Complete Protease Inhibitor (Roche)) and mixed
with NuPage LDS 4X sample buffer (Invitrogen). Samples were
boiled for 10 minutes, separated on a 4–12% Bis-Tris gel
(Invitrogen), and transferred to a PVDF membrane (Immobilon-
P, Millipore). To detect dFMR1, membranes were incubated with
anti-dfmr1 antibody (5A11) 1:2000 (DSHB, Iowa). To detect the
loading controls, actin and b-tubulin, membranes were incubated
with anti-actin (JLA20) 1:2000 (DSHB) or anti-b-tubulin (E7)
1:2000 (DSHB).
Supporting Information
Figure S1 dFMR1 protein levels are increased in heads and
ovaries from ago2 mutant flies. (A) Western analysis of head
extracts from: WT, dfmr13, dfmr1(4X), Ago2414 and Ago251B.
Anti-dFMR1 (5A11) was used to visualize dFMR1 levels. b-tubulin
was used as a loading control. (B) Quantification of dFMR1 levels
from head lysates was carried out with two biological replicates
(except for Ago2414 (carried out once) using Image Quant
software. The average relative levels of dFMR1 are represented as
the ratio of dFMR1 to b-tubulin and were normalized to WT.
Data are graphed as mean + s.d. (C) Western analysis of ovary
lysates from: WT, dfmr1(4X), Ago251B, and Ago2414. Actin was
used as a loading control. (D) Graphical representation of the
quantification of the western analyses in ovary lysates. Quantifi-
cation was carried out with two or more biological replicates as in
(B) except that Actin was used for normalization. Data are graphed
as mean + s.d. (Note that in panels A and C irrelevant lanes were
removed to simplify the presentation of the data. All of the samples
shown in each panel are derived from the same blot.)
Found at: doi:10.1371/journal.pone.0007618.s001 (0.74 MB TIF)
Figure S2 dfmr1 transcript levels are elevated in Ago2 null
ovaries. (A) Representative Northern blot for dfmr1 transcript
levels. Total ovary RNA samples were probed for dfmr1
transcripts (top panel) and b-tubulin (lower panel) to provide a
loading control. (B) dfmr1 RNA from WT, dfmr1(4X), and
Ago251B ovary lysates were quantified and averaged from 2 blots
using Image Quant software. The average levels of the dfmr1
transcript are represented as the ratio of dfmr1 levels to b-tubulin
levels and are normalized to transcript levels from WT tissue. Data
are graphed as mean 6 s.e.m.
Found at: doi:10.1371/journal.pone.0007618.s002 (0.32 MB TIF)
Figure S3 Ago2 does not require robust endoribonuclease
activity to regulate dFMR1 during oogenesis. Representative
images of whole-mount ovaries labeled for dFMR1 (green) from
WT and Ago2V966M flies. Scale bar is 26.65 mm. The graphs
plot the pixel intensity (0 to 255 as quantified by Leica software)
versus position (mm) along a line drawn through the egg chamber
(n.10 for each genetic background).
Found at: doi:10.1371/journal.pone.0007618.s003 (0.26 MB TIF)
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